Literature DB >> 22549804

Human tumor xenografts: the good, the bad, and the ugly.

Richard A Morgan1.   

Abstract

Entities:  

Mesh：

Year:  2012        PMID： 22549804      PMCID： PMC3345993          DOI： 10.1038/mt.2012.73

Source DB:  PubMed          Journal:  Mol Ther        ISSN： 1525-0016            Impact factor:   11.454


× No keyword cloud information.
  23 in total

1.  Cancer regression in patients after transfer of genetically engineered lymphocytes.

Authors:  Richard A Morgan; Mark E Dudley; John R Wunderlich; Marybeth S Hughes; James C Yang; Richard M Sherry; Richard E Royal; Suzanne L Topalian; Udai S Kammula; Nicholas P Restifo; Zhili Zheng; Azam Nahvi; Christiaan R de Vries; Linda J Rogers-Freezer; Sharon A Mavroukakis; Steven A Rosenberg
Journal:  Science       Date:  2006-08-31       Impact factor: 47.728

Review 2.  Humanized mice in translational biomedical research.

Authors:  Leonard D Shultz; Fumihiko Ishikawa; Dale L Greiner
Journal:  Nat Rev Immunol       Date:  2007-02       Impact factor: 53.106

3.  Heterotransplantation of a human malignant tumour to "Nude" mice.

Authors:  J Rygaard; C O Povlsen
Journal:  Acta Pathol Microbiol Scand       Date:  1969

4.  Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines.

Authors:  Jeongwu Lee; Svetlana Kotliarova; Yuri Kotliarov; Aiguo Li; Qin Su; Nicholas M Donin; Sandra Pastorino; Benjamin W Purow; Neil Christopher; Wei Zhang; John K Park; Howard A Fine
Journal:  Cancer Cell       Date:  2006-05       Impact factor: 31.743

Review 5.  Microenvironmental regulation of metastasis.

Authors:  Johanna A Joyce; Jeffrey W Pollard
Journal:  Nat Rev Cancer       Date:  2008-03-12       Impact factor: 60.716

6.  A severe combined immunodeficiency mutation in the mouse.

Authors:  G C Bosma; R P Custer; M J Bosma
Journal:  Nature       Date:  1983-02-10       Impact factor: 49.962

7.  Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice.

Authors:  L D Shultz; P A Schweitzer; S W Christianson; B Gott; I B Schweitzer; B Tennent; S McKenna; L Mobraaten; T V Rajan; D L Greiner
Journal:  J Immunol       Date:  1995-01-01       Impact factor: 5.422

Review 8.  The EGFRvIII variant in glioblastoma multiforme.

Authors:  Hui K Gan; Andrew H Kaye; Rodney B Luwor
Journal:  J Clin Neurosci       Date:  2009-03-25       Impact factor: 1.961

9.  Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling.

Authors:  Chrystal M Paulos; Claudia Wrzesinski; Andrew Kaiser; Christian S Hinrichs; Marcello Chieppa; Lydie Cassard; Douglas C Palmer; Andrea Boni; Pawel Muranski; Zhiya Yu; Luca Gattinoni; Paul A Antony; Steven A Rosenberg; Nicholas P Restifo
Journal:  J Clin Invest       Date:  2007-08       Impact factor: 14.808

Review 10.  Of mice and men: values and liabilities of the athymic nude mouse model in anticancer drug development.

Authors:  L R Kelland
Journal:  Eur J Cancer       Date:  2004-04       Impact factor: 9.162
View more
  18 in total

Review 1.  [Combination of Oncolytic Virotherapy and CAR T/NK Cell Therapy for the Treatment of Cancer].

Authors:  G V Kochneva; G F Sivolobova; A V Tkacheva; A A Gorchakov; S V Kulemzin
Journal:  Mol Biol (Mosk)       Date:  2020 Jan-Feb

Review 2.  Comparative transcriptomics in human and mouse.

Authors:  Alessandra Breschi; Thomas R Gingeras; Roderic Guigó
Journal:  Nat Rev Genet       Date:  2017-05-08       Impact factor: 53.242

Review 3.  Minimum information reporting in bio-nano experimental literature.

Authors:  Matthew Faria; Mattias Björnmalm; Kristofer J Thurecht; Stephen J Kent; Robert G Parton; Maria Kavallaris; Angus P R Johnston; J Justin Gooding; Simon R Corrie; Ben J Boyd; Pall Thordarson; Andrew K Whittaker; Molly M Stevens; Clive A Prestidge; Christopher J H Porter; Wolfgang J Parak; Thomas P Davis; Edmund J Crampin; Frank Caruso
Journal:  Nat Nanotechnol       Date:  2018-09-06       Impact factor: 39.213

Review 4.  Best Practices for Preclinical In Vivo Testing of Cancer Nanomedicines.

Authors:  Danielle M Valcourt; Chintan H Kapadia; Mackenzie A Scully; Megan N Dang; Emily S Day
Journal:  Adv Healthc Mater       Date:  2020-05-04       Impact factor: 9.933

5.  EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss.

Authors:  John H Sampson; Bryan D Choi; Luis Sanchez-Perez; Carter M Suryadevara; David J Snyder; Catherine T Flores; Robert J Schmittling; Smita K Nair; Elizabeth A Reap; Pamela K Norberg; James E Herndon; Chien-Tsun Kuan; Richard A Morgan; Steven A Rosenberg; Laura A Johnson
Journal:  Clin Cancer Res       Date:  2013-12-18       Impact factor: 12.531

6.  Skeletal impact of 17β-estradiol in T cell-deficient mice: age-dependent bone effects and osteosarcoma formation.

Authors:  Julia N Cheng; Jennifer B Frye; Susan A Whitman; Janet L Funk
Journal:  Clin Exp Metastasis       Date:  2019-12-20       Impact factor: 5.150

7.  Transgenic Expression of IL15 Improves Antiglioma Activity of IL13Rα2-CAR T Cells but Results in Antigen Loss Variants.

Authors:  Giedre Krenciute; Brooke L Prinzing; Zhongzhen Yi; Meng-Fen Wu; Hao Liu; Gianpietro Dotti; Irina V Balyasnikova; Stephen Gottschalk
Journal:  Cancer Immunol Res       Date:  2017-05-26       Impact factor: 11.151

8.  Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma.

Authors:  Richard A Morgan; Laura A Johnson; Jeremy L Davis; Zhili Zheng; Kevin D Woolard; Elizabeth A Reap; Steven A Feldman; Nachimuthu Chinnasamy; Chien-Tsun Kuan; Hua Song; Wei Zhang; Howard A Fine; Steven A Rosenberg
Journal:  Hum Gene Ther       Date:  2012-09-24       Impact factor: 5.695

9.  A rational mouse model to detect on-target, off-tumor CAR T cell toxicity.

Authors:  Mauro Castellarin; Caroline Sands; Tong Da; John Scholler; Kathleen Graham; Elizabeth Buza; Joseph A Fraietta; Yangbing Zhao; Carl H June
Journal:  JCI Insight       Date:  2020-07-23

10.  Preparation of an Orthotopic, Syngeneic Model of Lung Adenocarcinoma and the Testing of the Antitumor Efficacy of Poly(2-oxazoline) Formulation of Chemo-and Immunotherapeutic Agents.

Authors:  Natasha Vinod; Duhyeong Hwang; Salma H Azam; Amanda E D Van Swearingen; Elizabeth Wayne; Sloane Christian Fussell; Marina Sokolsky-Papkov; Chad V Pecot; Alexander V Kabanov
Journal:  Bio Protoc       Date:  2021-03-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.